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Chitosan nanoparticles for nitric oxide delivery in human skin  
M. T. Pelegrino,
a,b
  R. Weller,
c
  X. Chen,
c
  J. S. Bernardes,
d
 and A. B. Seabra
b* 
The use of nanoparticle-based transdermal delivery systems is a promising approach to efficiently carry and deliver 
therapeutic agents for dermal and systemic administration. Nitric oxide (NO) is a key molecule that plays important roles 
in human skin such as the control of skin homeostasis, skin defense, control of dermal blood flow, and wound healing. In 
addition, human skin contains stores of NO derivatives that can be mobilized and release free NO upon UV irradiation with 
beneficial cardiovascular effects, for instance the control of blood pressure. In this work, the NO donor precursor 
glutathione (GSH) was encapsulated (encapsulation efficiency of 99.60%) into ultra-small chitosan nanoparticles (CS NPs) 
(hydrodynamic size of 30.65 ± 11.90 nm). GSH-CS NPs have a core-shell structure, as revealed by atomic force microscopy 
and X-ray photoelectron spectroscopy, in which GSH is protected in the nanoparticle core. Nitrosation of GSH by nitrous 
acid led to the formation of the NO donor S-nitrosogluthathione (GSNO) into CS NPs. The GSNO release from the CS NPs 
followed a fickian diffusion described by Higuchi mathematical model. Topical application of GSNO-CS NPs in intact human 
skin significantly increased NO and its derivatives levels in the epidermis, as assayed by confocal microscopy, and this 
effect was further enhanced by skin irradiation with UV light. Therefore, NO-releasing CS NPs are suitable materials for 
transdermal NO delivery to local and/or systemic therapies.
Introduction  
 
The free radical nitric oxide (NO) is an important signaling molecule 
involved in several physiologic and pathophysiologic processes in 
mammals including the dilation of blood vessels, the immune 
response, antioxidant and anticancer activities, cell communication, 
and the inhibition of platelet adhesion and aggregation, among 
others.
1-6 
NO is an important molecule synthesized by several skin 
cells, and due to its chemical nature (small size, lack of charge and 
lipophilicity) it easily diffuses among cells and tissues playing 
important roles in the bioregulation of several processes in human 
skin, such the promotion of wound healing, the control of dermal 
blood flow, erythema formation, skin defense and pigmentation.
7,8
 
NO is endogenously synthesized by a family of three nitric oxide 
synthase (NOS) enzymes: endothelial (eNOS), neuronal (nNOS) and 
inducible (iNOS).
9-11
 Both eNOS and nNOS express constitutive NO 
for homeostatic activities, such as the control of blood flow, skin 
pigmentation and the delay of wrinkle onset.
12,13
 In contrast, iNOS 
produces higher amounts of NO in response to cell-specific stimuli.
6
 
The three NOS isoforms are expressed in human skin cells.  
Topical applications of NO-releasing biomaterials are able to 
increase dermal blood flow in human health volunteers
14,15
 and 
diabetic rats
16
 to promote and accelerate tissue repair of acute,
17,18
 
and ischaemic,
19
 to combat cutaneous infections caused by 
bacteria,
20
 protozoa,
21
 and fungi,
22
 and to have toxic effects against 
skin cancer.
23
 In addition, several papers reported that the human 
skin contains stores of NO derivatives, present as oxidized forms of 
NO, predominantly nitrate (NO3
-
), nitrite (NO2
-
), and S-nitrosothiols 
(RSNOs), which can be mobilized to release free NO to the systemic 
circulation upon UV irradiation producing beneficial effects on 
cardiovascular health by controlling blood pressure and obesity.
24-29
 
In addition, Mowbray et al. demonstrated that skin exposure of 
healthy subjects to physiological quantities of UVA irradiation 
increased arterial vasodilation and decreased blood pressure.
30
 
Although sunlight exposure is a risk factor for skin cancer, it also 
increases NO bioavailability leading to cardiovascular benefits.  
Due to the importance of NO in biological system, there is an 
increasing interest in developing vehicles able to carry and to 
deliver therapeutic amounts of NO in human skin, where NO may 
have local and/or systemic effects.
31-33
 In this work, the low 
molecular weight NO donor S-nitrosoglutathione (GSNO) was 
incorporated into chitosan nanoparticles (CS NPs) for topical NO 
delivery in human skin in order to enhance the cutaneous NO 
derivatives stores. Chitosan is a biopolymer obtained through the 
desacetylation of chitin and employed for several biomedical 
applications including gene and drug delivery and treatment of 
wound infections, due to its unique properties such as 
biocompatibility, biodegradability, antimicrobial, antioxidant, and 
mucoadhesion characters.
34- 37 
Recently, engineered nanoparticles 
have been successfully applied in topical delivery systems.
38-40
 In 
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particular, ultra-small polymeric nanoparticles (smaller than 40 nm) 
show superior penetration into skin strata, carrying and delivering 
active molecules to the desired site of application.
41
  
In this context, this work describes the synthesis and 
characterization of ultra-small GSNO-containing CS NPs and the 
kinetic profiles and mechanisms of GSNO release from the 
nanoparticles under physiological conditions. Moreover, GSNO-CS 
NPs were topically applied on ex vivo human skin sections and the 
intracutaneous distribution and enrichment of NO through the 
epidermis was quantified.  To our best knowledge, this is the first 
work to report the effects of UV irradiation on skin sections pre-
treated with NO-releasing nanoparticles. GSNO-CS NPs have 
chemical, structural, and morphological properties suitable for 
efficient transdermal delivery of NO in human skin. The results 
highlight the potential therapeutic effects of combined 
administration of GSNO-CS NPs and UV irradiation to efficiently 
load NO in human skin for local and/or systemic (cardiovascular) 
applications.  
 
Results and Discussion  
 
Synthesis and characterization of GSH-CS NPs  
The combination of low molecular weight NO donors, such as 
GSNO, with nanoparticles has been extensively explored to allow 
the delivery of the unstable NO molecules directly to the 
therapeutic site in a sustained and safe manners.
31-33
 Biocompatible 
and biodegradable polymeric nanoparticles are promising platforms 
for drug delivery.
33
 The polysaccharide chitosan is widely used in 
topical drug delivery system due to its mucoadhesion, antioxidant 
and antimicrobial activities.
34,36
 In the work we describe here, CS 
NPs were obtained based on the cross-linking between positively 
charged chitosan chains and the negatively charged polyanion 
TPP.
42
 The tripeptide GSH, precursor of the NO donor GSNO, was 
encapsulated into CS NPs via electrostatic interactions. DLS 
measurements revealed that the hydrodynamic size, polydispersity 
index (PDI), and zeta potential of GSH-CS NPs were 30.65 ± 11.90 
nm, 0.258 ± 0.008, and + 26.1 ± 0.5 mV, respectively. These results 
confirm the formation of GSH-CS NPs in the nanoscale with a 
monodal size distribution due to the electrostatic interactions 
between chitosan, TPP and GSH. Figure S1 of the Supporting 
Information shows a representative size distribution curve of the 
GSH-CS NPs obtained by DLS measurements, and the corresponding 
autocorrelation curve, showing a monodal size distribution. The 
obtained PDI value suggested a minor particle polydispersity. The 
positive zeta potential value is attributed to the positive charge 
excess of protonated amino and thiol groups from GSH and amino 
groups from chitosan at low pH (2.75), which is in agreement with 
the charge balance of the system. It should be noted that positively 
charged nanoparticle surfaces might interact better with 
biomolecules/biological targets with negative charges, such as DNA 
or tumor surfaces, highlighting the importance of CS NPs in the 
biological medium.
43
 
Chemical surface composition of GSH-CS NPS was acquired by 
XPS and then compared to the total composition of the system. 
Carbon, oxygen, nitrogen, sulfur and phosphorous elements are all 
present at the nanoparticles surface, as shown in Table S1 of the 
Supporting Information. However, the molar ratio of GSH and 
chitosan, calculated from the values shown in Table S1, varies 
considerably, being 17.5:1 for the total composition and 2.8:1 for 
the nanoparticle surface. These results indicate that the outer 
surface layer of GSH-CS NPs is richer in chitosan and depleted in 
GSH, compared to the core.   
AFM was used to further understand the surface structure and 
the average size of GSH-CS NPs at solid state. Topography and 
phase contrast images from different areas were simultaneously 
acquired and some representative micrographs are displayed in 
Figure 1. 
 
 
Figure 1. AFM topographic (left) and phase contrast (right) images 
of GSH-CS NPs (GSH concentration of 100 mmol L
-1
). 
 
As can be observed in Figure 1 A and C, nanoparticles are 
approximately uniform spheres, with average diameter of 21.7 ± 3.8 
nm. These results are in agreement with the hydrodynamic size 
measured by DLS (30.65 ± 11.90 nm), since DLS value is expected to 
be higher than the size obtained by AFM due to the hydration of 
the NP surface.
44
 For topical applications, the skin penetration of 
ultra-small nanoparticles, with size smaller than 40 nm, is enhanced 
into the skin strata via hair follicle steam cells, allowing a superior 
dermatological application.
41
 
Another important aspect shown by AFM is that the inner part 
of the nanoparticles is darker than the shell as shown by the white 
arrows in the phase contrast image (Figure 1 B and D), reinforcing 
that the chemical composition of the core and shell are distinct, as 
detected by XPS analysis. The encapsulation efficiency of GSH in CS 
NPs was found to be 99.60 ± 0.01 %. Such high value reveals the 
strong electrostatic interaction between GSH and the NP 
components, indicating the success of nanoparticle preparation.  
All these observations can be used to propose a nanostructure 
model for GSH-CS NPS, as shown in Figure S2 of the Supporting 
Information, they have a core-shell structure with GSH 
encapsulated (with a high encapsulation efficiency) within the CS 
NP core.  
The encapsulation of GSH would protect the molecule from 
degradation while promoting a sustained release of the active drug. 
The core-shell structured nanoparticles are very suitable carrier 
system for drug delivery and have advantages over simple 
nanoparticles, such as, increase dispersibility, biocompatibility and 
chemical stability.
45
 Important therapeutic agents, such as plasmid 
DNA,
46
 and acyclovir
47
 were successfully incorporated into CS NPs. 
The incorporation of therapeutic molecules into CS NPs would 
increase drug thermal and photochemical stabilities, while 
enhanced drug permeation through the skin.
41
 CS NPs have been 
employed to deliver plasmid DNA and antisense oligonucleotides 
for topical skin deliver applications.
41
  
 
GSNO release profiles in vitro from free and encapsulated GSNO  
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The thiol group of free or encapsulated GSH was nitrosated by 
reacting with an equimolar amount of NaNO2 in acidified solution 
leading to the formation of free or GSNO-CS NPs. GSNO act as 
spontaneous NO donor due to the homolytic bond cleavage with 
free NO release and the formation of oxidized glutathione (GS-SG) 
(Figure 2). This reaction occurs thermally and can be catalyzed by 
irradiation with UV or visible light.
48,49
  
 
 
 
Figure 2. Nitrosation of glutathione (GSH) by sodium nitrite (NaNO2) 
yielding S-nitrosoglutathione (GSNO) (A), which thermally or 
photochemically releases free NO (B). 
 
Once encapsulated in CS NPs, GSNO is expected to diffuse from 
the polymeric matrix to the exterior solution, where the intact 
GSNO releases free NO by S-N cleavage. Therefore, the release of 
intact GSNO molecule from the CS NPs was monitored by using a 
Franz diffusion cell. Figure 3 shows the kinetics of GSNO release 
from CS NPs, compared to the diffusion of free GSNO. As can be 
observed, the GSNO release profiles comprise two sequential 
phases. Firstly, GSNO is rapidly released from the donor 
compartment to the receptor compartment through the 
membrane, in the first 2.5 h of monitoring. Secondly, the rates of 
GSNO release from the donor compartment of the Franz diffusion 
cell to the receptor compartment significantly decreased, for both 
free and encapsulated GSNO, creating a steady state, which 
continues for at least 4.5 h. This profile is in accordance with 
kinetics studies for encapsulated GSNO in chitosan/alginate 
nanoparticles reported by Wu et al.
50
 
 
 
 
Figure 3. In vitro percentage of cumulative GSNO release from: (i) 
free GSNO, and (ii) GSNO-CS NPs, using a vertical Franz diffusion cell 
with a polysulfone membrane disc filter. Initial GSNO concentration 
of 10 mmol∙L
-1
. The error bars represent the mean of three 
independent experiments ± standard error. 
 
In order to elucidate the main release mechanism of GSNO from 
CS NPs, the Higuchi mathematical model was applied on the kinetic 
curves of Figure 3. The correlation coefficients (r²) of 0.991 and 
0.995 for free GSNO and for GSNO-CS NPs, respectively, were 
obtained. This result indicates a fickian diffusion of the GSNO (free 
or encapsulated into CS NPs), which corroborates with previous 
study reported by our group.
51
 
The release constants (KH) of GSNO were 15.650 ± 0.456 and 
7.751 ± 1.228 %·h
-0.5
 for free GSNO for GSNO-CS NPs, respectively. It 
should be noted that the KH value of the free GSNO is 2-fold higher 
in comparison with the value obtained for GSNO encapsulated into 
CS NPs. Furthermore, the total GSNO released from CS NPs was 
found to be ca. 12% of the initial amount of encapsulated NO donor 
after 4 h 30 min of monitoring. In contrast, GSNO released through 
the membrane reached ca. 30% of the initial amount of GSNO after 
the same period of monitoring. These results indicate that the 
encapsulation of GSNO into CS NPs promoted a sustained GSNO 
diffusion.  
NO release from GSNO-CS NPs is expected to occur following 
the processes: (i) intact GSNO is released from the nanoparticles 
core to the exterior medium, where GSNO would release free NO 
by its thermal or photochemical decomposition,
52
 and/or intact 
GSNO may react with cysteine residues of important proteins in 
trans-nitrosation reactions,
53
 outside of the nanoparticles; (ii) GSNO 
is decomposed within the polymeric nanoparticle yielding free NO, 
which diffuses through the polymeric layer of the nanoparticle to 
the exterior medium. In both cases, a sustained GSNO/NO released 
is obtained upon incorporated of the NO donor into CS NPs. In a 
similar manner, Duong at al. reported that the encapsulation of 
GSNO into polymeric nanoparticles significantly improved NO 
stability.
54
  
 
Topical application of GSNO-CS NPs: NO loading in human skin  
GSNO-CS NPs (GSNO concentration of 100 mmol·L
-1
) were topically 
applied on ex vivo human skin sections to investigate the NO 
permeating through the skin and the NO loading in the epidermis 
upon skin treatment with the nanoparticles, in the dark and under 
UV light irradiation. We selected to irradiate skin sections with UV 
light of 290 nm for 20 minutes since previous investigation from this 
group revealed that this is the optimal irradiation condition for 
increasing NO pool in human skin (data not shown). Figures 4 A and 
B show the representative confocal florescence microscopy images 
of human skin sections: untreated (A) and treated with GSNO-CS 
NPs for 6 h, in the dark.  All the skin sections were pre-incubated 
with the NO fluorochrome. Topical application of GSNO-CS NPs 
increased cutaneous fluorescence intensity (Fig. 4B) most markedly 
in the epidermis and stratum corneum, compared to untreated skin 
(control group) (Fig. 4A). Figure 4 C shows the fluorescence 
intensities of human skin sections: (i) untreated (control group); (ii) 
pre-treated with GSH-CS NPs, (iii) pre-treated with GSNO-CS NPs; in 
the dark or followed by UV irradiation ( = 290 nm) for 20 min. It 
can be observed that topical application of GSNO-CS NPs 
significantly increased fluorescence intensities, in the dark and 
followed UV irradiation for 20 min, compared with the other 
groups. Indeed, dermal application of NO-releasing nanoparticles 
increased in ca. 2-fold the NO pool in comparison with topically 
applied GSH-CS NPs. Moreover, irradiation of skin sections with UV 
light increased the fluorescence intensities in all groups, compared 
non-irradiated skin sections (dark condition). The combination of 
skin pre-treated with GSNO-CS NPs followed by UV irradiation led 
to the highest increase in the NO fluorescence signal intensity in the 
epidermis (Figure 4 C). In fact, a 2.3-fold increase in the 
fluorescence intensity was found for skin sections treated with NO-
releasing nanoparticles, compared with GSH-CS NPs, for irradiated 
groups. 
ARTICLE Journal Name 
4 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
 
 
Figure 4. NO permeation through ex vivo human skin sections upon 
treatment with GSNO-CS NPs (GSNO concentration of 100 mmol∙L
-1
) 
for 6 h, followed by 20 minutes of UV irradiation, compared with 
dark condition. Confocal florescence microscopy images of human 
skin were acquired through incubation of the skin sections with the 
NO fluorochrome 4,5-diaminofluorescein diacetate (DAF-2DA) for 
24 hours prior the addition of: GSNO-CS NPs, GSH-CS NPs, and no 
treatment (untreated skin sections). Representative images of 
human skin sections: (A) untreated skin in the dark; and (B) skin 
treated with GSNO-CS NPs in the dark. (C) Means of fluorescence 
intensities due to the presence of NO in the epidermis of skin 
sections (n = 6) of: (i) untreated skin in the dark; (ii) pre-treated skin 
with GSH-CS NPs in the dark; (iii) pre-treated skin with GSNO-CS NPs 
in the dark; (iv) untreated skin under UV irradiation for 20 min; (v) 
pre-treated skin with GSH-CS NPs followed by UV-irradiation for 20 
min and (vi) pre-treated skin with GSNO-CS NPs followed by UV-
irradiation for 20 min. UV irradiation with 290 nm. * P < 0.05 and 
AU, arbitrary units. 
 
Taking together, these results demonstrated that topical 
application of GSNO-CS NPs in the dark and under UV light 
irradiation significantly increased NO pool in human skin. Both 
treatments led to the highest NO detection in the epidermis. 
NO is key signaling and modulator molecule in many tissues and 
organs, including human skin. NO is continuously synthesized in the 
human skin by several cells.
12,13
. Important papers demonstrated 
that topical applications of NO promotes and accelerates wound 
healing,
17-19 
controls skin homeostasis,
55
 increases dermal blood 
flow,
14,15 
and has protective functions in skin defense against 
pathogens and cancer condition.
12,13 
As a small lipophilic free 
radical, NO has a diffusion coefficient of ca. 3300 µm
2
/s at 37°C,
56
 
which is comparable to similar small and neutral diatomic 
molecules.
57
 Therefore, NO is expected to have a diffusion distance 
of 500 µm in tissues, allowing its penetration to the dermis and 
epidermis, upon topical application.
58
 Following a cutaneous 
application, NO has the ability to rapidly penetrates the lipid-rich 
structure of the stratum corneum barrier due to its chemical 
nature.
59
 Hence, following topical application, NO might exert local 
effects such as the increase of dermal blood flow,
14,15 
regulation of 
apoptosis following UV radiation, wound healing and regulation of 
keratinocyte homeostasis.
30 
 
Nanoparticles have been extensively employed in several 
biomedical applications, including transdermal and dermal delivery 
of therapeutic agents and antimicrobial applications.
40,60-62
 The 
chemical composition, size, surface components, and charge of the 
nanoparticles dictate their performance in dermatological drug 
delivery systems.
40,41
 In this work, the NO delivery though human 
skin was performed by applying GSNO-CS NPs. Our results 
demonstrated that CS NPs have a small size and positive zeta 
potential, making them suitable for NO delivering through the skin. 
The positive charges of CS NPs facilitate the affinity with negatively 
charged phospholipids, altering the skin membrane permeability 
and thus reducing the skin barrier properties.
63,64 
Interestingly, the 
CS NPs synthesized in this work have a small size (less than 40 nm 
as assayed by DLS and AFM), which facilitates the nanoparticle 
penetration through human skin via trans-appendageal routes. 
Several studies demonstrated that nanoparticles smaller than 40 
nm can reach hair follicles after topical application to animal and 
human skin.
39,41,65,66 
 
Penetration of nanoparticles through the skin may occurs via 
lipid channels and/or follicular route. Due to the particular 
properties of GSNO-CS NPs, the intact NO-releasing nanoparticle 
are able to penetrate into the superficial layers of the stratum 
corneum, and then release the encapsulated GSNO and/NO locally 
into the deeper skin layers. Alternatively, the nanoparticles may 
remain in the outer layers of the stratum corneum and epidermis, 
where GSNO and/or NO is released and permeated through the 
skin. In both manners, topical application of GSNO-CS NPs 
significantly increased the NO pool in the epidermis, suggesting that 
this material might find important applications for transdermal NO 
delivery therapies, including the treatment of disturbed dermal 
circulation, wound infections and skin ulceration.
28,29
  
Figure 4 shows that UV light irradiation increases NO levels in 
the skin, and a significant enhancement of cutaneous NO stores was 
achieved by the combination of skin pre-treated with GSNO-CS NPs 
followed by UV light irradiation. Previous studies demonstrated that 
human skin contains large stores of NO derivatives (nitrite, nitrate, 
S-nitrosothiols, NO-heme species), which release free NO upon UV 
irradiation.
24-29
 Figure 4 indicates that there are NO stores within 
human skin that are able to release NO upon UV irradiation, and 
topical administration of NO-releasing nanoparticles has the ability 
to replenish the endogenous NO stores in human skin. Moreover, 
UV light irradiation efficiently catalyzes the decomposition of skin 
permeated GSNO in the skin layers leading to the formation of 
bioactive NO.
28,29
 It has been demonstrated that NO and its 
derivatives, generated in the skin under UV irradiation, have the 
ability to influence the cardiovascular system controlling several 
disorder such as hypertension, thrombosis, injury and 
atherosclerosis.
59,67,68
 
  
UV light administration to healthy subjects decreased blood 
pressure, and thus the risk for stroke and coronary heart diseases.
27 
UV light induced beneficial cardiovascular effects that require 
cutaneous bioactive NO rather than NO in bloodstream.
69
 It should 
be noted that the deleterious effects of sunlight are well known, 
such as, skin cancer and premature aging.
70
 Topical application of 
GSNO-CS NPs enhanced NO levels in the epidermis, which may have 
a protective effect against negative effects of UV irradiation due to 
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the increases of Bcl-2 expression and concomitant inhibition of 
UVA-induced overexpression of Bax protein.
28,29,71
 It should be 
noted that depletion of skin NO stores may occur following 
prolonged UV irradiation with reduced clinical benefit. Topical 
application of NO-releasing CS NP might revert this depletion by 
efficiently loading NO to the skin.  
 
Conclusions 
This paper describes the synthesis and characterization of 
ultra-small GSNO-CS NPs and their topical application to intact 
human skin. The nanoparticles consist of a core-shell structure, 
this configuration allows the protection of the encapsulate 
molecule promoting a sustained release of the active drug. 
Topical application of GSNO-CS NPs on intact human skin 
significantly increase the levels of NO in the epidermis, 
indicating the transdermal efficacy of NO-releasing CS NPs. The 
combination of cutaneous administration of GSNO-CS NPs 
followed by skin UV irradiation further enhanced the NO and 
its derivatives loaded in human skin. To our best knowledge, 
this is the first report to demonstrate the efficacy of NO-
releasing CS NPs in cutaneous application.  
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